Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftriaxone in Mild to Moderate Parkinson's Disease Dementia
NCT03413384Phase 2Completed
- Sponsor
- BrainX
- Start
- Feb 2019
- Primary completion
- Jul 2025
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of ceftriaxone in Parkinson's disease dementia (PDD), sponsored by BrainX. Started Feb 2019; status: completed.
02
Drugs
ceftriaxone
03
Conditions
Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on NCT03413384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03413384.